Haoyuan Pharmaceutical's Wholly-Owned Subsidiary Passes U.S. FDA Inspection with Zero Deficiencies

CLS··CNUS·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Haoyuan Pharmaceutical announced that its wholly-owned subsidiary, Yaoyuan Biotech Qidong Co., Ltd., passed a U.S. FDA pre-approval inspection with zero deficiencies. The subsidiary underwent the inspection from June 22 to 26, 2026, and recently received the on-site inspection report confirming the result. This marks the first time its finished dosage manufacturing site has passed a U.S. FDA inspection, which will help the company expand in the U.S. market and have a positive impact on its operating performance and international competitiveness.

Impact on assets 1

Others▲ · 1 stocks

Off-coverage companies 1

药源生物科技（启东）有限公司Private▲ Positive
Regulationrelevance

The subsidiary itself passed the FDA inspection, directly benefiting its operations.

© 2026 MarketIVNews